AdaptHealth (AHCO)
Market Price (12/4/2025): $9.33 | Market Cap: $1.3 BilSector: Health Care | Industry: Health Care Equipment
AdaptHealth (AHCO)
Market Price (12/4/2025): $9.33Market Cap: $1.3 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.8%, FCF Yield is 18% | Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -129% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 151% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18% | ||
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Geriatric Care, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.8%, FCF Yield is 18% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Remote Patient Monitoring, Geriatric Care, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -129% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 151% |
Valuation, Metrics & Events
AHCO Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
AdaptHealth (AHCO) experienced a decrease in net revenue and adjusted EBITDA in the second quarter of 2025.
**1. Decrease in Net Revenue and Adjusted EBITDA in Q2 2025.**
AdaptHealth announced its second quarter 2025 results on August 5, 2025, reporting a net revenue of $800.4 million, a decrease of 0.7% compared to $806.0 million in the same period of 2024. Additionally, Adjusted EBITDA for Q2 2025 was $155.5 million, marking a decrease of 5.9% from $165.3 million in Q2 2024.
**2. Lower Net Income in Q2 2025.**
Net income attributable to AdaptHealth Corp. in the second quarter of 2025 was $14.7 million, down from $19.4 million in the second quarter of 2024.
**3. Updated Financial Guidance for Fiscal Year 2025.**
The company updated its financial guidance for fiscal year 2025, revising net revenue to a range of $3.18 billion to $3.26 billion (from $3.15 billion to $3.29 billion) and Adjusted EBITDA to $642 million to $682 million (from $662 million to $702 million).
**4. S&P Global Ratings Upgrade for Senior Unsecured Debt.**
On November 17, 2025, AdaptHealth Corp. announced that S&P Global Ratings upgraded its issue-level rating on the company's senior unsecured debt to 'BB-' from 'B+' and revised its recovery rating.
**5. Partnership with a Major National Healthcare System.**
AdaptHealth Corp. partnered with a major national healthcare system to become the exclusive provider of home medical equipment, as announced on August 5, 2025.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AHCO Return | 242% | -35% | -21% | -62% | 31% | -1% | -14% |
| Peers Return | 38% | 32% | -15% | 2% | 16% | 1% | 86% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| AHCO Win Rate | 75% | 50% | 42% | 33% | 42% | 60% | |
| Peers Win Rate | 54% | 67% | 46% | 58% | 60% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| AHCO Max Drawdown | -4% | -51% | -53% | -66% | -9% | -23% | |
| Peers Max Drawdown | -25% | -11% | -45% | -25% | -22% | -14% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: EW, MASI, ATRC, UFPT, DAVI.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | AHCO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -83.8% | -25.4% |
| % Gain to Breakeven | 518.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -38.0% | -33.9% |
| % Gain to Breakeven | 61.3% | 51.3% |
| Time to Breakeven | 15 days | 148 days |
| 2018 Correction | ||
| % Loss | -21.3% | -19.8% |
| % Gain to Breakeven | 27.1% | 24.7% |
| Time to Breakeven | 22 days | 120 days |
Compare to EW, MASI, ATRC, UFPT, DAVI
In The Past
AdaptHealth's stock fell -83.8% during the 2022 Inflation Shock from a high on 2/1/2021. A -83.8% loss requires a 518.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to AHCO. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 4.1% | 4.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -9.8% | -9.8% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.0% | 6.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 9.7% | 9.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 6.2% | 6.2% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for AdaptHealth
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 83.98 |
| Mkt Cap | 1.7 |
| Rev LTM | 2,182 |
| Op Inc LTM | 133 |
| FCF LTM | 168 |
| FCF 3Y Avg | 93 |
| CFO LTM | 208 |
| CFO 3Y Avg | 147 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.8% |
| Rev Chg 3Y Avg | 11.4% |
| Rev Chg Q | 8.2% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | 6.6% |
| Op Mgn 3Y Avg | 8.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 16.6% |
| CFO/Rev 3Y Avg | 13.5% |
| FCF/Rev LTM | 7.7% |
| FCF/Rev 3Y Avg | 5.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.7 |
| P/S | 3.3 |
| P/EBIT | 4.6 |
| P/E | 14.7 |
| P/CFO | 38.3 |
| Total Yield | 3.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.6% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 2.8% |
| 3M Rtn | 3.4% |
| 6M Rtn | 4.0% |
| 12M Rtn | -2.5% |
| 3Y Rtn | -5.1% |
| 1M Excs Rtn | 2.8% |
| 3M Excs Rtn | -3.5% |
| 6M Excs Rtn | -10.7% |
| 12M Excs Rtn | -20.4% |
| 3Y Excs Rtn | -75.5% |
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Sleep Health | 1,292 | ||||
| Diabetes Health | 660 | ||||
| Wellness at Home | 634 | ||||
| Respiratory Health | 615 | ||||
| Diabetes | 687 | 541 | 162 | ||
| Home medical equipment (HME) | 221 | 210 | 114 | 85 | |
| Other | 262 | 186 | 71 | 44 | |
| Respiratory | 555 | 458 | 152 | 87 | |
| Sleep | 1,067 | 891 | 411 | 305 | |
| Supplies to the home | 179 | 168 | 146 | 8 | |
| Total | 3,200 | 2,971 | 2,455 | 1,056 | 530 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/30/2025 |
| 6302025 | 8052025 | 10-Q 6/30/2025 |
| 3312025 | 5062025 | 10-Q 3/31/2025 |
| 12312024 | 2252025 | 10-K 12/31/2024 |
| 9302024 | 11052024 | 10-Q 9/30/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5072024 | 10-Q 3/31/2024 |
| 12312023 | 2272024 | 10-K 12/31/2023 |
| 9302023 | 11072023 | 10-Q 9/30/2023 |
| 6302023 | 8082023 | 10-Q 6/30/2023 |
| 3312023 | 5092023 | 10-Q 3/31/2023 |
| 12312022 | 2282023 | 10-K 12/31/2022 |
| 9302022 | 11082022 | 10-Q 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5102022 | 10-Q 3/31/2022 |
| 12312021 | 3012022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |